Abstracts tagged "Outcome measures and polymyalgia rheumatica"

Abstract Number: 2767 • 2014 ACR/ARHP Annual Meeting
Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (PMR) Using Omeract Filter 2.0
Sarah Mackie¹, Toby Helliwell², Rodney Hughes³, E Brouwer⁴, Colin T. Pease⁵, Christian Mallen⁶, Maarten Boers⁷ and John R. Kirwan⁸, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Primary Care and Health Sciences, Keele University, Staffordshire, United Kingdom, ³Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ⁷Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ⁸Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom
Background/Purpose The OMERACT PMR specialist interest group was established to develop a core outcome measurement set for PMR using the methods of OMERACT filter 2.0.…
Abstract Number: 1924 • 2012 ACR/ARHP Annual Meeting
What Do Patients with Polmyalgia Rheumatica Mean When They Describe Stiffness? A Qualitative Study
Rodney A. Hughes¹, Sarah Mackie², John R. Kirwan³, Colin T. Pease⁴, Margaret Walsh¹ and Marianne Morris⁵, ¹Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom, ²Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ⁴Department of Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵University of the West of England, Bristol, United Kingdom
Background/Purpose: Patients with PMR report significant symptoms of pain and stiffness. Stiffness has usually been included in diagnostic criteria for PMR but has never been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].